You are here: Home :: Area NEM :: Medical science :: Human medicine :: Internal medicine

D. P. Chew

Bivalirudin, ein bivalentes, thrombinspezifisches Antikoagulans als Alternative zu Heparin bei Interventionen

Among the antithrombotic therapies evaluated to date, the synthetic peptide bivalirudin is unique in its ability to reduce both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is a small peptide consisting of 20 amino acid residues that binds thrombin in a direct, reversible, and bivalent fashion. The agent is approved for use in the United States and New Zealand as an anticoagulant in patients with unstable angina undergoing PCI and may also prove beneficial in patients with acute coronary syndromes (ACS), acute myocardial infarction (AMI) and in patients undergoing coronary artery bypass graft (CABG) procedures. This article examines bivalirudin in more detail.

Hämostaseologie, Schattauer

Print ISSN: 0720-9355
Volume: 22, 01/2002
Pages: 60 - 66

Show full article (external site)

Show all available items of this journal

 

Area NEM